{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:01:12Z","timestamp":1773270072251,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,7,10]],"date-time":"2004-07-10T00:00:00Z","timestamp":1089417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,7,10]],"date-time":"2004-07-10T00:00:00Z","timestamp":1089417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1007\/s00280-004-0837-7","type":"journal-article","created":{"date-parts":[[2004,7,9]],"date-time":"2004-07-09T15:45:03Z","timestamp":1089387903000},"page":"385-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma"],"prefix":"10.1007","volume":"54","author":[{"given":"Jeeyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Hyoek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Cheol","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Woon","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Chul","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewon","family":"Joh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,7,10]]},"reference":[{"key":"837_CR1","first-page":"8","volume":"32","author":"Al-Idrissi","year":"1985","unstructured":"Al-Idrissi HY, Ibrahim EM, Abdel Satir A, Satti MB, Al-Kasem S, Al-Qurain A (1985) Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C. Hepatogastroenterology 32:8\u201310","journal-title":"Hepatogastroenterology"},{"key":"837_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4143\/crt.2002.34.2.77","volume":"34","author":"Bae","year":"2002","unstructured":"Bae JM, Won YJ, Jung KW, Park JG (2002) Annual report of the Korea Central Cancer Registry Program 2000. Cancer Res Treat 34:77\u201383","journal-title":"Cancer Res Treat"},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-002-0503-x","volume":"50","author":"Boucher","year":"2002","unstructured":"Boucher E, Corbinais S, Brissot PI, Boudjema K, Raoul JL (2002) Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 50:305\u2013308","journal-title":"Cancer Chemother Pharmacol"},{"key":"837_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bjc.1998.438","volume":"78","author":"Chao","year":"1998","unstructured":"Chao Y, Chan WK, Birkhofer MK, Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD (1998) Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78:34\u201339","journal-title":"Br J Cancer"},{"key":"837_CR5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0168-8278(05)80243-0","volume":"18","author":"Chlebowski","year":"1993","unstructured":"Chlebowski RT, Brezechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK (1993) Doxorubicin (75\u00a0mg\/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. J Hepatol 18:168\u2013172","journal-title":"J Hepatol"},{"key":"837_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/0959-8049(95)00323-B","volume":"31A","author":"Ellis","year":"1995","unstructured":"Ellis PA, Norman A, Hill A, O\u2019Brien ME, Nicolson M, Hickish T, Cunningham D (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31A:1594\u20131598","journal-title":"Eur J Cancer"},{"key":"837_CR7","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/1097-0142(19871101)60:9<2141::AID-CNCR2820600903>3.0.CO;2-4","volume":"60","author":"Falkson","year":"1987","unstructured":"Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BI, Carbone PP, Creech RH, Schutt AJ (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60:2141\u20132145","journal-title":"Cancer"},{"key":"837_CR8","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/0360-3016(83)90352-8","volume":"9","author":"Friedman","year":"1983","unstructured":"Friedman MA (1983) Primary hepatocellular cancer\u2014present results and future prospects. Int J Radiat Oncol Biol Phys 9:1841\u20131843","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"837_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","volume":"62","author":"Lai","year":"1988","unstructured":"Lai CL, Wu PC, Chan GC, Lok AS, Lin HG (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479\u2013483","journal-title":"Cancer"},{"key":"837_CR10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000658-199503000-00012","volume":"221","author":"Lai","year":"1995","unstructured":"Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J (1995) Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221:291\u2013298","journal-title":"Ann Surg"},{"key":"837_CR11","first-page":"103","volume":"29","author":"Lee","year":"1997","unstructured":"Lee JA, Kang YK, Kim CM, Lee JO, Kang TW (1997) A phase II study of doxorubicin, cisplatin chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Res Treat 29:103\u2013110","journal-title":"Cancer Res Treat"},{"key":"837_CR12","first-page":"1676","volume":"5","author":"Leung","year":"1999","unstructured":"Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676\u20131681","journal-title":"Clin Cancer Res"},{"key":"837_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cncr.10236","volume":"94","author":"Leung","year":"2002","unstructured":"Leung TW, Tang AMY, Zee B, Yu SCH, Lai P, Lau WY, Johnson PJ (2002) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94:421\u2013427","journal-title":"Cancer"},{"key":"837_CR14","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1111\/j.1440-1746.1997.tb00516.x","volume":"12","author":"Lin","year":"1997","unstructured":"Lin DY, Lin SM, Liaw YF (1997) Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S319\u2013S328","journal-title":"J Gastroenterol Hepatol"},{"key":"837_CR15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62\u201367","journal-title":"Hepatology"},{"key":"837_CR16","first-page":"264a","volume":"19","author":"Lozano","year":"2000","unstructured":"Lozano RD, Patt YZ, Hassan MM (2000) Oral capecitabine for the treatment of hepatobiliary cancers. Proc Am Soc Clin Oncol 19:264a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"837_CR17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207\u2013214","journal-title":"Cancer"},{"key":"837_CR18","first-page":"248a","volume":"18","author":"Okada","year":"1999","unstructured":"Okada S, Okusaka T, Ueno H (1999) Phase II trial of cisplatin, mitoxantrone, and continuous infusion 5-fluorouracil (5-FU) (FMP therapy) for hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 18:248a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"837_CR19","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/1097-0142(19800515)45:10<2663::AID-CNCR2820451030>3.0.CO;2-G","volume":"45","author":"Okuda","year":"1980","unstructured":"Okuda K (1980) Primary liver cancers in Japan. Cancer 45:2662\u20132672","journal-title":"Cancer"},{"key":"837_CR20","first-page":"164a","volume":"21","author":"Rai","year":"2002","unstructured":"Rai K, Tsuji A, Morita S (2002) Continuous infusion of 5-FU and low-dose consecutive CDDP therapy in advanced hepatocellular carcinoma: a phase II study (abstract). Proc Am Soc Clin Oncol 21:164a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"837_CR21","first-page":"1517","volume":"68","author":"Ravry","year":"1984","unstructured":"Ravry M, Omura G, Bartolucci A (1984) Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep 68:1517\u20131518","journal-title":"Cancer Treat Rep"},{"key":"837_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"837_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1008285123736","volume":"8","author":"Simonetti","year":"1997","unstructured":"Simonetti RG, Liberati A, Angiolini C, Pagliaro L (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8:117\u2013136","journal-title":"Ann Oncol"},{"key":"837_CR24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1053\/he.2000.5628","volume":"31","author":"The","year":"2000","unstructured":"The Cancer of the Liver Italian Program (CLIP) Investigators (2000) Prospective validation of CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840\u2013845","journal-title":"Hepatology"},{"key":"837_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R","volume":"89","author":"Yang","year":"2000","unstructured":"Yang TS, Lin YC, Chen JS, Wang HM, Wang CH (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750\u2013756","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-004-0837-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0837-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:36:00Z","timestamp":1659058560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-004-0837-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s00280-004-0837-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,10]]},"assertion":[{"value":"23 October 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}